Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5092150
Max Phase: Preclinical
Molecular Formula: C38H56N14O12
Molecular Weight: 900.95
Molecule Type: Unknown
Associated Items:
ID: ALA5092150
Max Phase: Preclinical
Molecular Formula: C38H56N14O12
Molecular Weight: 900.95
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(N)=O
Standard InChI: InChI=1S/C38H56N14O12/c1-19(47-35(62)25(4-3-13-44-38(41)42)50-36(63)27(48-20(2)53)14-21-5-7-23(54)8-6-21)33(60)52-28(15-22-16-43-18-46-22)37(64)51-26(9-11-29(39)55)34(61)45-17-30(56)49-24(32(40)59)10-12-31(57)58/h5-8,16,18-19,24-28,54H,3-4,9-15,17H2,1-2H3,(H2,39,55)(H2,40,59)(H,43,46)(H,45,61)(H,47,62)(H,48,53)(H,49,56)(H,50,63)(H,51,64)(H,52,60)(H,57,58)(H4,41,42,44)/t19-,24-,25-,26-,27-,28-/m0/s1
Standard InChI Key: RHAIHGCXUIGQLX-LXLNESOMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 900.95 | Molecular Weight (Monoisotopic): 900.4202 | AlogP: -5.16 | #Rotatable Bonds: 28 |
Polar Surface Area: 437.99 | Molecular Species: ZWITTERION | HBA: 13 | HBD: 15 |
#RO5 Violations: 3 | HBA (Lipinski): 26 | HBD (Lipinski): 18 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.96 | CX Basic pKa: 11.58 | CX LogP: -8.53 | CX LogD: -8.56 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.02 | Np Likeness Score: 0.05 |
1. Lior Y, Shtriker E, Kahremany S, Lewis EC, Gruzman A.. (2022) Development of anti-inflammatory peptidomimetics based on the structure of human alpha1-antitrypsin., 228 [PMID:34763945] [10.1016/j.ejmech.2021.113969] |
Source(1):